Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1973 1
1976 1
1977 3
1980 2
1981 1
1986 1
1987 2
1988 1
1989 1
1990 1
1991 2
1992 1
1994 1
1995 3
1996 1
1997 3
1998 1
1999 3
2000 3
2001 1
2002 5
2003 3
2004 4
2005 1
2007 1
2008 4
2009 4
2010 3
2011 5
2012 11
2013 8
2014 7
2015 11
2016 9
2017 3
2018 3
2019 16
2020 6
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

133 results
Results by year
Filters applied: . Clear all
Page 1
Satellite Cells and Skeletal Muscle Regeneration.
Dumont NA, Bentzinger CF, Sincennes MC, Rudnicki MA. Dumont NA, et al. Compr Physiol. 2015 Jul 1;5(3):1027-59. doi: 10.1002/cphy.c140068. Compr Physiol. 2015. PMID: 26140708 Review.
WRN helicase is a synthetic lethal target in microsatellite unstable cancers.
Chan EM, Shibue T, McFarland JM, Gaeta B, Ghandi M, Dumont N, Gonzalez A, McPartlan JS, Li T, Zhang Y, Bin Liu J, Lazaro JB, Gu P, Piett CG, Apffel A, Ali SO, Deasy R, Keskula P, Ng RWS, Roberts EA, Reznichenko E, Leung L, Alimova M, Schenone M, Islam M, Maruvka YE, Liu Y, Roper J, Raghavan S, Giannakis M, Tseng YY, Nagel ZD, D'Andrea A, Root DE, Boehm JS, Getz G, Chang S, Golub TR, Tsherniak A, Vazquez F, Bass AJ. Chan EM, et al. Among authors: dumont n. Nature. 2019 Apr;568(7753):551-556. doi: 10.1038/s41586-019-1102-x. Epub 2019 Apr 10. Nature. 2019. PMID: 30971823 Free PMC article.
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.
Corsello SM, Nagari RT, Spangler RD, Rossen J, Kocak M, Bryan JG, Humeidi R, Peck D, Wu X, Tang AA, Wang VM, Bender SA, Lemire E, Narayan R, Montgomery P, Ben-David U, Garvie CW, Chen Y, Rees MG, Lyons NJ, McFarland JM, Wong BT, Wang L, Dumont N, O'Hearn PJ, Stefan E, Doench JG, Harrington CN, Greulich H, Meyerson M, Vazquez F, Subramanian A, Roth JA, Bittker JA, Boehm JS, Mader CC, Tsherniak A, Golub TR. Corsello SM, et al. Among authors: dumont n. Nat Cancer. 2020 Feb;1(2):235-248. doi: 10.1038/s43018-019-0018-6. Epub 2020 Jan 20. Nat Cancer. 2020. PMID: 32613204 Free PMC article.
Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.
Prussick L, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Abdat R, Alomran A, Zancanaro P, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D. Prussick L, et al. Among authors: dumont n. Br J Dermatol. 2019 Sep;181(3):609-611. doi: 10.1111/bjd.17822. Epub 2019 May 12. Br J Dermatol. 2019. PMID: 30801662 Clinical Trial. No abstract available.
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, Almanza D, Dempster JM, Pan J, Piccioni F, Dumont N, Gonzalez A, Rennhack J, Nabet B, Bachman JA, Goodale A, Lee Y, Bagul M, Liao R, Navarro A, Yuan TL, Ng RWS, Raghavan S, Gray NS, Tsherniak A, Vazquez F, Root DE, Firestone AJ, Settleman J, Hahn WC, Aguirre AJ. Sulahian R, et al. Among authors: dumont n. Cell Rep. 2019 Oct 1;29(1):118-134.e8. doi: 10.1016/j.celrep.2019.08.090. Cell Rep. 2019. PMID: 31577942 Free PMC article.
Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial.
Casseres RG, Prussick L, Zancanaro P, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Au SC, Alomran A, Abdat R, Abudu M, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D. Casseres RG, et al. Among authors: dumont n. J Am Acad Dermatol. 2020 Jun;82(6):1524-1526. doi: 10.1016/j.jaad.2020.02.005. Epub 2020 Feb 7. J Am Acad Dermatol. 2020. PMID: 32044410 Clinical Trial. No abstract available.
133 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page